Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 200,623
  • Shares Outstanding, K 52,519
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,730 K
  • 60-Month Beta 3.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.22
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.64 +4.95%
on 03/25/19
4.69 -18.55%
on 04/09/19
-0.03 (-0.78%)
since 03/18/19
3-Month
2.95 +29.49%
on 01/23/19
4.69 -18.55%
on 04/09/19
+0.60 (+18.63%)
since 01/18/19
52-Week
2.36 +61.86%
on 12/21/18
10.54 -63.76%
on 10/01/18
-1.18 (-23.60%)
since 04/18/18

Most Recent Stories

More News
New Research Coverage Highlights Quanta Services, Kansas City Southern, Oceaneering International, Marinus Pharmaceuticals, Allegion, and Craft Brew Alliance -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanta Services, Inc. (NYSE:PWR),...

PWR : 40.01 (-0.20%)
ALLE : 93.75 (-0.16%)
KSU : 125.03 (+1.81%)
BREW : 13.91 (+0.36%)
OII : 17.25 (+0.17%)
MRNS : 3.82 (-4.02%)
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

MRNS : 3.82 (-4.02%)
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings

Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.

KALV : 25.50 (+0.43%)
TCEHY : 50.3700 (+0.20%)
ORCL : 54.52 (+0.07%)
MRNS : 3.82 (-4.02%)
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?

Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.

AVGO : 318.62 (-0.60%)
KALV : 25.50 (+0.43%)
TCEHY : 50.3700 (+0.20%)
MRNS : 3.82 (-4.02%)
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business...

MRNS : 3.82 (-4.02%)
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 3.82 (-4.02%)
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 3.82 (-4.02%)
Marinus Announces Leadership Transition

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) ("Marinus" or the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 3.82 (-4.02%)
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 3.82 (-4.02%)
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 3.82 (-4.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade MRNS with:

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

2nd Resistance Point 4.08
1st Resistance Point 3.95
Last Price 3.82
1st Support Level 3.73
2nd Support Level 3.64

See More

52-Week High 10.54
Fibonacci 61.8% 7.42
Fibonacci 50% 6.45
Fibonacci 38.2% 5.48
Last Price 3.82
52-Week Low 2.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar